Exchange: Other OTC Sector: Healthcare Industry: Medical - Devices
13.03% $0.175
/ 28 mar 2024 @ 14:46
FUNDAMENTALS | |
---|---|
MarketCap: | 4.51 mill |
EPS: | -1.580 |
P/E: | -0.110 |
Earnings Date: | Apr 15, 2024 |
SharesOutstanding: | 25.74 mill |
Avg Daily Volume: | 0.104 mill |
RATING 2024-03-28 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Sell | |
DE: | Strong Sell | |
P/E: | Neutral | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.110 | sector: PE 0 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE -0.110 | industry: PE 0 |
DISCOUNTED CASH FLOW VALUE |
---|
$-0.0055 (-103.17%) $-0.181 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 0.137 - 0.213 ( +/- 21.69%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-27 | Urdea Michael S | Buy | 2 872 | Common Stock |
2024-03-27 | Schumacher Richard T | Buy | 4 554 | Common Stock |
2024-03-27 | Pollack Kevin | Buy | 2 914 | Common Stock |
2024-03-27 | Peterson Jeffrey N | Buy | 11 874 | COMMON STOCK |
2024-03-27 | Mangiardi Vito J | Buy | 625 | COMMON STOCK |
INSIDER POWER |
---|
100.00 |
Last 100 transactions |
Buy: 2 740 363 | Sell: 0 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.175 (13.03% ) |
Volume | 0.0576 mill |
Avg. Vol. | 0.104 mill |
% of Avg. Vol | 55.67 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was incorporated in 1978 and is based in South Easton, Massachusetts. As of August 2, 2022, Pressure BioSciences, Inc. operates as a subsidiary of Emergent Health Corp.